Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.

导出 OA

翻译打印收藏纠错

作者： Alexander,Streuer ^[1] ; Johann-Christoph,Jann ^[2] ; Tobias,Boch ^[2] ; Maximilian,Mossner ^[3] ; Vladimir,Riabov ^[2] ; Nanni,Schmitt ^[2] ; Eva,Altrock ^[2] ; Qingyu,Xu ^[2] ; Marie,Demmerle ^[2] ; Verena,Nowak ^[2] ; Julia,Oblaender ^[2] ; Iris,Palme ^[2] ; Nadine,Weimer ^[2] ; Felicitas,Rapp ^[2] ; Georgia,Metzgeroth ^[2] ; Anna,Hecht ^[2] ; Thomas,Höger ^[4] ; Christian,Merz ^[4] ; Wolf-Karsten,Hofmann ^[2] ; Florian,Nolte ^[2] ; Daniel,Nowak ^[2]

作者单位： Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Pettenkoferstr. 22, 68169, Mannheim, Germany. alexander.streuer@medma.uni-heidelberg.de. ^[1] Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Pettenkoferstr. 22, 68169, Mannheim, Germany. ^[2] Centre for Genomics and Computational Biology, Barts Cancer Institute, London, UK. ^[3] Apogenix GmbH, Heidelberg, Germany. ^[4]

关键词 APG101 Apoptosis inhibitor Asunercept Myelodysplastic Neoplasms Targeted therapies

主题词人类(Humans);肿瘤(Neoplasms);骨髓增生异常综合征(Myelodysplastic Syndromes);克隆细胞(Clone Cells);骨髓(Bone Marrow);细胞凋亡(Apoptosis);突变(Mutation)

DOI 10.1007/s00277-024-05664-5

PMID 38413410

发布时间 2024-03-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交